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ABSTRACT 
One of the insidious biological features of gliomas is potential to invade normal brain tissue 
extensively, yet molecular mechanisms that dictate this locally invasive behavior remain poorly 
understood. To investigate the molecular basis of invasion by malignant gliomas, proteomic analysis 
was performed using a pair of canine glioma subclones—J3T-1 and J3T-2—that show different 
invasion phenotypes in rat brains but have similar genetic backgrounds. Two-dimensional protein 
electrophoresis of whole-cell lysates of J3T-1 (angiogenesis-dependent invasion phenotype) and 
J3T-2 (angiogenesis-independent invasion phenotype) was performed. Twenty-two distinct spots 
were recognized when significant alteration was defined as more than 1.5-fold change in spot 
intensity between J3T-1 and J3T-2. Four proteins that demonstrated increased expression in J3T-1, 
and 14 proteins that demonstrated increased expression in J3T-2 were identified using liquid 
chromatography-mass spectrometry analysis. One of the proteins identified was annexin A2, which 
was expressed at higher levels in J3T-1 than in J3T-2. The higher expression of annexin A2 in J3T-1 
was corroborated by quantitative reverse transcription-PCR of the cultured cells and 
immunohistochemical staining of the rat brain tumors. Moreover, immunohistochemical analysis of 
human glioblastoma specimens showed that annexin A2 was expressed at high levels in the tumor 
cells that formed clusters around dilated vessels. These results reveal differences in the proteomic 
profiles between these two cell lines that might correlate with their different invasion profiles. Thus, 
4 
 
annexin A2 may be related to angiogenesis-dependent invasion. 
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INTRODUCTION 
 Gliomas are highly invasive and tend to diffusely infiltrate the brain, thereby placing 
tumor cells outside the margins of therapeutic resection. The mechanisms of invasion by glioma 
cells have been addressed in different studies and experimental settings, yet there is a need for a 
novel panel of biomarkers that characterize each invasive phenotype. Moreover, invasive nests of 
tumor cells are associated with initiation of neovascular angiogenesis and disruption of the 
blood-brain barrier through release of vasomodulatory cytokines. Taken together, these factors 
contribute to the rapid invasion process that is beyond the confines of the typical radiologically 
identifiable tumor mass, resulting in the near universally high rate of tumor recurrence and ultimate 
death. 
 Little is known about the distinct biology of invasive gliomas in situ, but their diffuse 
invasion profile suggests the activation of genetic and cellular mechanisms that distinguish them 
from the cells inside the tumor’s core. Systematic analysis of tumor cells with different biological 
behaviors may help to elucidate the nature of each tumor’s invasion pattern. Currently, the proteomic 
approach has made it possible to characterize the global alterations that occur in cellular protein 
expression. This proteomics-based analysis promises new insights into the cellular mechanisms 
involved in tumor invasion and is likely to result in the discovery of novel diagnostic markers and 
new therapeutic targets. 
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 In our previous study, detailed histopathological observations of human glioblastoma 
tissue revealed that there are at least two invasive and angiogenic phenotypes: one dependent on 
angiogenesis and the other independent of angiogenesis. Glioma cells migrate along dilated vessels 
in angiogenesis-dependent invasion, while infiltration of single glioma cells into the brain tissue is 
unrelated to the vasculature in angiogenesis-independent invasion.1,2 Moreover, we established two 
glioma cell lines (J3T-1 and J3T-2) that showed different invasion phenotypes when implanted in rat 
brains.1,2 J3T-1 cells form comparatively well-demarcated and highly angiogenic tumors, while 
J3T-2 cells form tumors with obscure margins via single-cell infiltration into the normal brain 
parenchyma. J3T-1 and J3T-2 cells show angiogenesis-dependent and independent invasive patterns, 
respectively, in rat brain tumor models; these patterns resemble those of human glioblastoma 
invasion. 
 In the present study, this pair of cell lines was examined using a proteomics approach, 
including the use of two-dimensional gel electrophoresis (2DGE) and liquid chromatography-tandem 
mass spectrometry analysis (LC-MS/MS), to compare the proteomic profiles of these two cell lines 
with different invasion phenotypes. 
 
MATERIALS AND METHODS 
Cell Culture 
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 The J3T canine glioma cell was a generous gift from Michael E. Berens MD, PhD 
(Translation Genomics Research Institute, Phoenix, AZ, USA).3 Two cell lines—J3T-1 and 
J3T-2—were developed from the parental J3T cell line, as previously described.1,4 In brief, J3T cells 
(5 × 106 cells) were subcutaneously implanted into the flanks of two athymic mice (NCr/Sed, nu/nu, 
20 g). After 6 weeks, two tumors were established in each animal. These tumors were harvested in a 
sterile fashion, minced with a scalpel into 1-mm3 cubes, treated for 1 h with 1 mg/ml 
Collagenase/Dispase (Roche, Basel, Switzerland), and subsequently cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units penicillin, 
and 0.1 mg streptomycin per milliliter. Both cell lines were derived from single subcutaneous 
tumors. 
 For enhanced visualization of J3T-1 and J3T-2 cells, cell lines were established that stably 
expressed green fluorescent protein (GFP), as previously described.1 In brief, J3T-1 and J3T-2 cells 
were transfected with the pAcGFP1-C1 plasmid (Clontech Laboratories Inc, Mountain View, CA, 
USA), which encodes for GFP using the TransIT-LT1 reagent (Takara Bio Inc, Otsu, Japan) to 
obtain J3T-1G and J3T-2G, respectively. Cells were cultured in DMEM supplemented with 10% 
FBS, 100 units penicillin, and 0.1 mg streptomycin per milliliter in a standard tissue incubator at 
37°C with a 5% CO2 atmosphere. 
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2DGE 
 The cells were washed with a solution of phosphate-buffered saline (PBS) that contained 
0.27% CaCl2・H2O, 0.02% MgCl2・6H2O, 1% FBS, and 5 mM sodium pyruvate. Cells were 
harvested by mechanical scraping during the exponential growth phase. Cells were then centrifuged, 
and the cell pellets were dissolved in a lysis buffer that consisted of 5 M urea, 2 M thiourea, 2% 
3-(3-cholamidopropyl)dimethylammonio-1-propane sulfonate (CHAPS), 2% sulfobetaine 3-10 
(SB3-10), 1% dithiothreitol (DTT), and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, 
USA). After three freeze-thaw cycles, the cell pellets were sonicated for 30 s and ultracentrifuged at 
75,000 ×g for 30 min at 10°C using the OptimaTM TLX ultracentrifuge (Beckman Coulter, Brea, CA, 
USA). The supernatant was transferred to a new tube and treated with ReadyPrep 2D Cleanup Kit 
(Bio-Rad, Hercules, CA, USA) to remove any ions, DNA, RNA, etc. The protein concentration was 
estimated using the RC-DC Protein Assay kit (Bio-Rad) according to manufacturer with two-washed 
standard protocol. For isoelectric focusing (IEF), Carrier ampholyte 5/8 (Bio-Rad) was formulated to 
increase the resolution at the basic end of the flatbed isoelectric focusing gel. 
 The first-dimensional IEF was performed using a 17-cm immobilized nonlinear pH 
gradient (5-8) strip (DryStrip; Bio-Rad). After rehydration for 15 h in a 300-μl buffer that consisted 
of 5M urea, 2M thiourea, 2% CHAPS, 3% SB3-10, 1% DTT, and 0.2% Bio-Lyte® 5/8 ampholyte 
(Bio-Rad), 60-μg samples of each protein were loaded onto the strips. Focusing was performed in 
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following step; (I) 250 V with linear increase for 40 min, (II)10000 V with linear increase for 4 h and 
(III) 10000 V with rapid increase for 7 h (total 70000V-hr); the samples were then maintained at 500 
V, as needed. 
 The focused strips were then equilibrated in buffer I (6 M urea, 2% sodium dodecyl sulfate 
(SDS), 0.375 M Tris-HCl, 20% glycerol, and 2% DTT; pH 8.8) for 30 min and then buffer II (6 M 
urea, 2% SDS, 0.375 M Tris-HCl, 20% glycerol, and 2.5% iodoacetamide; pH 8.8) for 15 min with 
gentle shaking. The second-dimensional separation was carried out on 12% SDS-polyacrylamide 
gels using PROTEAN II Cell (Bio-Rad) at 20°C and 40 mA/gel for 4 h. 
 After 2DGE, the gels were stained with SYPRO Ruby (Invitrogen, Carlsbad, CA, USA) 
and Dodeca Silver Stain Kits (Bio-Rad), according to the manufacturer’s protocol. Each experiment 
was performed in triplicate. 
 
Image Analysis of 2DGE Gels 
 Images of the SYPRO Ruby-stained gels were obtained using a FLA-3000 image analyzer 
(Fujifilm, Tokyo, Japan). The images were analyzed using PDQuest Advanced, version 8.0 
(Bio-Rad); analysis included background subtraction, spot detection, and volume normalization. The 
intensity of each spot was quantified by calculating the spot volume after normalization to the local 
regression model. The intensities of three sets of matched spots of each J3T-1 and J3T-2 gel were 
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compared, and a threshold ratio of 1.5 was used to screen for differences. Visual inspection 
confirmed the differences indicated by PDQuest analysis. 
 
Protein Identification 
 The selected protein spots were manually excised from the gels after visualizing the spots 
with silver staining. After destaining and drying the excised spots, in-gel trypsin digestion using the 
Protein In-Gel Tryptic Digestion kit (Agilent Technologies, Santa Clara, CA, USA) was performed 
overnight at 30°C. The obtained peptide digests were analyzed using a fully automated nanoflow 
liquid chromatography-ion trap-tandem mass spectrometer (nLC-IT-MS/MS; Agilent 1100 LC/MSD 
Trap XCT Ultra, Agilent Technologies). 
 Protein identification was performed using the Spectrum Mill MS Proteomics Workbench 
platform (version A.03.02; Agilent Technologies), according to the workflow parameters specified 
by the manufacturer. The identification parameters were set as follows: database, NCBInr; species, 
Canis familialis; enzyme, trypsin; monoisotopic masses used; precursor mass tolerance (peptide 
tolerance), ±2.5 Da; product mass tolerance (MS/MS tolerance), ±0.8; fixed modification, 
carbamidomethylation (cysteine); and variable modification, oxidation (methionine). Two missed 
cleavages with trypsin were allowed and the instrument’s setting was specified as ‘‘ESI ion trap’’. 
The probability scores calculated by the software were used as the criteria for correct identification.  
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Quantitative reverse-transcription PCR (QRT-PCR)  
 Total RNA was isolated from cultured J3T-1 and J3T-2 cells using RNeasy® Mini Kit 
(QIAGEN, Valencia, CA, USA) and reverse-transcribed with oligo dT primers using SuperScript III 
First-Strand Synthesis System for RT-PCR (Invitrogen), according to manufacturer’s instructions. 
Primers specific for each target gene were designed using Primer Express (Applied Biosystems, 
Foster City, CA, USA) and synthesized by Invitrogen. The resulting cDNA was amplified by PCR 
using gene-specific primers and the 7300 Real Time PCR system (Applied Biosystems) and 
QuantiTectTM SYBR® Green PCR kit (QIAGEN). A log-linear relationship between the 
amplification curve and quantity of cDNA in the range of 1 to 1000 copies was observed. 
 The cycle number at the threshold was used as the threshold cycle (Ct). The different 
expression of mRNA was deducted from 2-ΔΔCt using the 7300 Real Time PCR System with the 
Sequence Detection software (version 1.4; Applied Biosystems). The amount of cDNA in each 
sample was normalized to the crossing point of the housekeeping gene GAPDH. The following 
thermal cycling parameters were used: denaturation at 95°C for 15 min, followed by 40 cycles of 30 
s at 94°C, 30 s at 55°C, and 1 min at 72°C. The relative mRNA upregulation for each gene in the 
J3T-2 cells was calculated using their respective crossing points in the following formula: 
F=2(TH−TG)-(OH−OG) 
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where, F = fold difference, T = J3T-2 cells, O = J3T-1 cells, 
H = housekeeping gene (GAPGH), and G = gene of interest. 
 
Immunohistochemistry 
All experimental animals were housed and handled in accordance with the Okayama 
University Animal Research Committee guidelines. Before implantation, 85–90% of the confluent 
J3T-1, J3T-2, J3T-1G, and J3T-2G cells were trypsinized, rinsed with a solution of DMEM and 10% 
FBS, and centrifuged at 800 rpm for 5 min. The resulting pellets were resuspended in PBS and the 
concentration was adjusted to 1 × 105 cells/μl of PBS. To establish the brain tumor models, athymic 
rats (F344/N-nu/nu; CLEA Japan, Inc., Tokyo, Japan) were anesthetized with an intraperitoneal 
injection of nembutal (30 mg/kg) and placed in a stereotactic apparatus (Narishige, Tokyo, Japan). 
Tumor cells (5 × 105 cells/5 μl) were slowly injected into the basal ganglia of the right cerebral 
hemisphere (4 mm lateral and 1 mm anterior to the bregma at a depth of 4 mm) using a Hamilton 
syringe (Hamilton, Reno, NV, USA), according to previously published procedures.1,5 For 
histological examination, the athymic rats (J3T-1, n = 5; J3T-2, n = 5) were sacrificed 4–5 weeks 
after tumor inoculation. Before sacrifice, the animals were anesthetized. Death was induced via 
cardiac puncture, then the animals were perfused with 100 ml PBS and fixated with 200 ml of 4% 
paraformaldehyde. The brains were removed and stored in 4% paraformaldehyde for at least 24 h. 
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Snap-frozen tissue samples were embedded in an optimal cutting temperature compound for 
cryosectioning. Sixteen-micrometer cryostat sections were processed for indirect 
immunofluorescence analysis. The slides were incubated with 10% horse serum in PBS at room 
temperature and then with the anti-annexin A2 antibody (1:20 mouse IgG; Zymed Laboratories, San 
Francisco, CA, USA) diluted with 1% horse serum in PBS, and stored overnight at 4°C. After three 
washes with PBS for 5 min, the slides were incubated with Cy3-conjugated antibodies against mouse 
IgG (1:300) (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and 4′, 
6-diamino-2-phenylindole in PBS (1:500; Invitrogen) for 60 min. The slides were then washed with 
PBS and mounted. 
 Human glioma samples were intraoperatively obtained from patients undergoing surgical 
removal of tumors for diagnostic and therapeutic purposes (Okayama University Hospital, Okayama, 
Japan). Written informed consent was taken in all the cases before surgery. Lobectomies were 
performed to remove the entire tumor and any surrounding brain parenchyma beyond the boundaries 
of the tumors observed on MRI. All glioma specimens were diagnosed and graded according to the 
World Health Organization classification of tumors of the central nervous system, and all five 
specimens were diagnosed as glioblastomas. No patient had received radiation or chemotherapy 
before surgery. 
 After deparaffinization in xylene and rehydration in decreasing concentrations of ethanol, 
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4-μm-thick sections were incubated in 0.3% hydrogen peroxide (30 min) and autoclaved with 
distilled water for 10 min at 121°C. After three washes in PBS, the sections were incubated with 
anti-annexin A2 monoclonal antibodies (1:20) (mouse IgG; Zymed Laboratories) that had been 
diluted with PBS and 5% skim milk (60 min) at room temperature. Secondary antibody was applied 
using the DakoCytomation Envision+ System-HRP kit, according to the manufacturer’s protocol 
(DakoCytomation, Carpinteria, CA, USA). The sections were visualized using 
3,3'-Diaminobenzidine (DAB). 
 Annexin A2 expression was qualitatively scored as follows: (-) for no staining (nearly 0% 
of cells were labeled), (+) for a trace of positive cells (less than 30% of cells were labeled), (++) for 
moderately diffuse staining or sparsely intensive staining (30%–60% of cells were labeled, and less 
than 30% of cells were labeled with the strong intensity), and (+++) for strongly diffuse staining 
(60%–100% of cells were labeled). T.M. and S.I. classified the tumors according to 3 representative 
fields without prior knowledge of the patients’ clinical or radiological data. 
 
RESULTS 
2DGE patterns and differential analysis of J3T-1 and J3T-2 
 The 2DGE gel images of J3T-1 and J3T-2 cells showed similar protein expression patterns, 
probably reflecting the genetic similarity of J3T-1 and J3T-2 (Fig. 1). 
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 Using the PDQuest 2DGE gel analysis software, approximately 2800 well-stained and 
clearly delineated protein spots were detected. Twenty-two spots showing more than 1.5-fold change 
in spot intensity; five of these protein spots were upregulated in J3T-1 and 17 were upregulated in 
J3T-2. These differentially expressed protein spots are illustrated with circles and spot numbers in 
Fig. 1A and 1B. 
 
Proteins identified by LC-MS/MS 
 Differentially expressed protein spots were excised from the 2DGE gels and analyzed for 
protein identification by LC-MS/MS and database searching. As a result, 18 proteins were identified 
in those spots; these proteins are shown in Table 1. The Spectrum Mill software calculates the 
MS/MS Search score as described below. Each peak assigned to an allowed fragment ion type for a 
candidate peptide sequence is given ''bonus points''. In contrast, each unassigned peak is given 
''penalty points''. Penalty value is based on peak height, - (peak height / height of tallest peak). 
MS/MS score is summation of these bonus points and penalty points, indicating probability of the 
protein. Thus, the higher score indicates the better probability. The identified proteins that were 
upregulated in J3T-1 included one metabolic enzyme, one storage protein, one structural protein, and 
one phospholipid-binding protein. Proteins that were upregulated in J3T-2 included eight metabolic 
enzymes, two translational regulatory proteins, two RNA-binding proteins, one GTP-binding protein, 
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and one signal transduction protein. Metabolic enzymes constituted more than half of the proteins 
that were upregulated in J3T-2. 
Fig. 2A and 2B shows the distribution of all the 18 identified proteins that were 
upregulated in J3T-1 and J3T-2 according to their general functions as described in NCBI Entrez 
Gene Database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) and Human Protein Reference 
Database (http://www.hprd.org/index_html). Fig. 2C shows the representative MS/MS 
spectrum for the peptide sequence matched to annexin A2 identified from spot No.4. 
 
Candidate protein validation by QRT-PCR 
 A summary of the QRT-PCR data is shown in Fig. 3. Similar patterns were observed for 
the gene expression profiles obtained with the proteomics and QRT-PCR data. The directionality of 
expression of 17 of the 18 genes coincided with the expression of the corresponding proteins. 
Fourteen of 18 genes demonstrated more than 1.5-fold change in expression (as denoted by the 
asterisks [*] in Fig. 3), while the rest of the proteins did not show marked difference in expression 
between J3T-1 and J3T-2 cells. 
 
Immunohistochemical corroboration of candidate proteins observed in the invasive animal 
models 
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 Representative photomicrographs of the invasive animal models are presented in Fig. 4A, 
B. J3T-1 cells formed well-demarcated and highly angiogenic tumors. In contrast, J3T-2 cells 
formed tumors with obscure margins via single-cell infiltration into the normal brain parenchyma.  
 The results of this proteomics-based analysis of the proteins involved in invasion were 
corroborated by immunohistochemical analysis of the J3T-1G and J3T-2G xenograft models. One of 
the identified proteins was annexin A2, which has been reported to be involved in tumor invasion 
and metastasis.6-8 Therefore, this protein was further studied using both animal models and human 
glioma samples. The annexin A2 antibody was readily available for immunohistochemical analysis 
of the frozen sections. Intense staining of the annexin A2 protein in the cytoplasm of the J3T-1 
tumor cells was observed, whereas almost no staining was observed in the J3T-2 tumor cells (Fig. 4 
C-H), as expected based on the results of the proteomic analysis. 
 
Immunohistochemical analysis of annexin A2 in human glioma samples 
 To analyze expression pattern of annexin A2 in relation to vasculature, 
immunohistochemical staining with anti-annexin A2 antibody was performed in 5 human 
glioblastoma samples. Patient’s age, sex, tumor locations, and degree of annexin A2 expression are 
summarized in Table 2. The center of the tumor comprised an area of high-density tumor cells which 
were negative or weakly positive for annexin A2. Marked angiogenesis, which was characterized by 
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thick endothelial proliferation, was seen in the center and at the tumor borders. At the borders, 
clusters of annexin A2-positive tumor cells were observed around dilated vessels in all cases (Fig. 
5A). Furthermore, diffuse single cell infiltration from the tumor core to the surrounding normal brain 
parenchyma, which was independent of vascular structure, was observed. Those cells were mostly 
negative (four cases) or weakly positive (one case; Patient 3) for annexin A2 (Fig. 5B). 
 
DISCUSSION 
 To investigate the molecular basis of the invasive properties of malignant gliomas, 
proteomic analysis of the invasion-related proteins was performed using two unique sibling glioma 
cell lines, J3T-1 and J3T-2, which exhibit different aspects of human glioma invasion in situ.  
 
Advantages of the proteomic method for identifying invasion-related proteins 
 This study describes how four proteins were observed in J3T-1 cells and 14 proteins were 
observed in J3T-2 cells, out of 2800 protein spots that were reproducibly identified on 2DGE gels at 
pH 5-8. 
 The similarities in the protein expression patterns on the 2DGE gel images of J3T-1 and 
J3T-2 cells reflect their genetic proximity. At the same time, significant differences in protein 
expression between these two cell lines do exist, which could be directly related to their invasive 
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characteristics. Taken together, the proteomic method could be used to sensitively capture the 
features of the cell lines used in this study. 
 The results of these proteomic analyses were corroborated by the results of the QRT-PCR 
and immunohistochemical analyses. Nearly all proteins that were shown to be upregulated by the 
2DGE method were also upregulated at the mRNA level. This method is simple, reproducible, and 
reliable and may prove useful for gaining a broader understanding of invasion in general as well as 
some of the advantages and pitfalls of other in vitro modeling systems. 
 As a shortcoming, 2DGE analysis usually cannot detect hydrophobic membrane proteins, 
proteins larger than 100 kDa, low-abundance proteins,9 or proteins with pI values outside the pH 
range.10 These limitations of standard 2DGE probably account for the less chance of this study to 
identify these types of proteins in J3T-1 and J3T-2 cells. 
 
Advantages of the two subclones for proteomic analysis 
 There are several advantages in using invasive animal models and proteomic analysis to 
study the molecular basis of glioma invasion. 
 First, the animal models used in this study are one of the few models available for studying 
invasive glioma in experimental settings.1,2 Traditional animal glioma models do not exhibit invasive 
growth into the surrounding normal brain areas and have been criticized for not recapitulating the 
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main pathological features of human glioma.11 Recently, several experimental glioma models 
showing varying degrees of invasion have been developed to study glioma cell invasion both in vitro 
and in vivo.12,13 
 Second, the two subclones that were established from the same parental cell line showed 
very different invasive phenotypes when inoculated in rat brains; however, the subclones have 
inherently similar genetic backgrounds.4 These differences in phenotypes are supposed to arise from 
differences in genotype. This allowed for direct comparison of the differentially expressed proteins 
that characterize the phenotypic differences in their invasive capabilities. 
 Third, the animal models used in this study are reproducible and suitable for in vivo 
experiments. Therefore, candidate proteins that might affect the invasive capability of the tumor can 
be directly verified in vivo using these animal models. 
 
Annexin A2 as a candidate invasion-related protein 
 One of the proteins identified, annexin A2, was expressed at higher levels in J3T-1 cells 
than in J3T-2 cells. Annexin A2 has been previously reported to be expressed on the tumor cell 
surface and to be involved in tumor invasion and metastasis.6-8 Therefore, this protein’s role in both 
animal models and human glioma samples was further examined. 
 Annexins are a superfamily of closely related calcium- and membrane-binding proteins 
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that are expressed in specific cell types. Annexins comprise numerous gene products, including 12 
that are formed in vertebrates (group A annexins), and have been proposed to be involved in a 
variety of functions, including control of membrane structures, vesicle trafficking, cell division, 
apoptosis, calcium signaling, and growth regulation.14-20 All annexins share a characteristic 
molecular structure that consists of a variable N-terminal domain and a highly conserved C-terminal 
domain, which is also called the annexin core. The core domain of annexin A2 harbors several 
Ca2+-binding sites and one actin-binding domain, whereas the N-terminal domain contains the 
binding site for the cellular ligand S100A10 and a Ca2+-independent membrane-binding domain. In 
cells, annexin A2 exists either as a monomer or as a heterotetrameric complex with S100A10.21 
Cell-surface annexin A2 has been shown to be a receptor/binding protein for both proteases 
(cathepsin B, plasminogen, and tissue-type plasminogen activator [tPA]) and extracellular matrix 
proteins (type I collagen and tenascin C) that are involved in tumor invasion and metastasis.6-8 tPA 
has been shown to bind specifically to annexin A2 on the extracellular membrane of pancreatic 
cancer cells where it activates plasmin production and promotes tumor cell invasion. Annexin A2 is 
also expressed on the surface of vascular endothelial cells and has been shown to play a significant 
role in the regulation of tPA activities, plasminogen activation, and angiogenic functions.22,23 
Increased expression of annexin A2 has been described in several types of tumor, including gastric 
carcinoma,24 colorectal cancer,25 pancreatic cancer,26 breast cancer,27 high-grade gliomas,28 kidney 
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cancer,29 and vascular tumors.30 In gliomas, annexin A2 has been identified more frequently in 
high-grade gliomas than in low grade gliomas10 and is known to be an independent prognostic factor 
for poor clinical outcomes in patients with gliomas.28,31 Because of the ability of annexin A2 to 
interact with the actin cytoskeleton14,15,32 and tumor-released proteases,15 annexin A2 has become a 
promising candidate for influencing the invasion processes of glioma cells. Recent proteomic 
investigations of the pseudopodia extensions of highly migratory U87MG glioma cells have reported 
increased levels of annexin A2.33 Tatenhorst et al. demonstrated that the migration of human glioma 
cells is significantly inhibited following annexin A2 depletion by RNA interference techniques in 
vitro.34 Moreover, cell-surface annexin A2 is a receptor for angiostatin, which is an internal fragment 
of plasminogen. Annexin A2-dependent localized plasmin generation could contribute to 
angiogenesis and metastasis. Therefore, by blocking annexin A2-dependent plasmin production, e.g., 
by using angiostatin, it may be possible to develop new anti-angiogenic therapies.35 
 A previous study reported that there are at least two invasive and angiogenic 
phenotypes—angiogenesis-dependent invasion and angiogenesis-independent invasion—and the 
novel animal glioma models used in this study were able to exhibit these phenotypes.1,2 The 
histopathological features of angiogenesis-dependent invasion are characterized by robust 
neovascular formation in the normal parenchyma adjacent to the main tumor mass and the formation 
of clusters of glioma cells. In contrast, angiogenesis-independent invasion is characterized by the 
23 
 
formation of poorly demarcated tumors that show single-cell infiltrations into the surrounding 
normal brain tissue without angiogenic activities. 
 In the present study, annexin A2 was upregulated in J3T-1 cells, which typically show 
angiogenesis-dependent invasion in rat brain. In addition, immunohistochemical analysis of human 
glioblastoma samples revealed that annexin A2 is expressed in clusters of tumor cells around dilated 
vessels located at the border of the tumor, suggesting that annexin A2 has a functional role in 
angiogenesis-dependent invasion. The authors consider that neo-angiogenesis is an important factor 
that contributes to the regulation of invasion patterns. Recent studies have shown that glioma cell 
lines derived from transgenic mice that lack VEGF expression form tumors with irregular borders 
and are highly invasive along blood vessels, as compared with the sharp borders seen in tumors 
derived from the glioma cells that have been transfected to overexpress VEGF.36 This observation is 
consistent with the result of the present study, suggesting that annexin A2 plays a key role in 
angiogenesis-dependent invasion by interacting with VEGF and other proangiogenic factors. With 
regard to the relationship between annexin A2 and VEGF, Zhao et al. demonstrated that the 
increased expression of annexin A2 in ischemic retinas is induced by increased levels of VEGF 
mRNA. Zhao et al. concluded that annexin A2 is a functional protein in VEGF expression in retinal 
neovascularization and is induced by hypoxia.37 
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Additional findings 
 Other noticeable proteins expressed higher in J3T-2 are heterogeneous nuclear 
ribonucleoproteins (hnRNPs) and Septin 11. 
 hnRNPs comprise a large family of proteins, including approximately 30 members that 
share some structural domains. The results obtained in our study show HNRNPK and HNRNPA1 are 
up-regulated in J3T-2. hnRNPs play important roles in telomere biogenesis, DNA repair, cellular 
signaling, and the regulation of expression at both the transcriptional and translational levels.38 In 
addition, the nuclear shift of HNRNPK in dividing cells suggests a role in proliferating cells.39 So far, 
there have been no detailed reports about functions of hnRNPs in gliomas. 
 Septins are a highly conserved subfamily of GTPases that play an important role in 
maintaining cytoskeletal structures necessary for the control of cell division, and are required for 
cytokinesis.40 Kim et al. showed that septins are variably expressed in human brain tumor cell lines 
and specimens using antibodies against septins 2, 3, 4, 5, 6, 7, 9, and 11 in immunofluorescence and 
Western blot analysis.41 In their study, septin 11 was immunolocalized along with the actin 
microfilamentous system, suggesting possible involvement in cell motility function. 
 These proteins are not fully investigated in terms of their function in glioma invasion and 
await further study. 
 
25 
 
CONCLUSION 
 Proteomic methods were used to compare the protein profiles of two cell lines with 
different invasive characteristics. This comparative analysis revealed the differential expression of 
several proteins that may be involved in tumor cell invasion. Among them, annexin A2 was shown 
to be one of the candidate proteins which are involved in angiogenesis-dependent invasion.  
 This study will help to elucidate the mechanisms involved in glioma cell invasion and will 
aid in the selection of targets for the molecular treatment of malignant gliomas. 
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Figure Legends 
Fig.1 SYPRO Ruby-stained two-dimensional gel electrophoresis (2DGE) gel images of J3T-1 
(A) and J3T-2 (B) cells. The arabic numbers indicate the differentially expressed spots; the numbers 
refer to those reported in Table 1. The protein expression levels of spots 1–5 were upregulated in 
J3T-1 cells. The protein expression levels of spots 6–22 were upregulated in J3T-2 cells. pI, 
isoelectric point; MW, molecular weight; Da, Daltons. 
 
Fig.2 Distribution of proteins according to their function and representative MS/MS spectrum. A 
and B: Pie charts representing the distribution of the identified proteins according to their general 
functions. Assignments were made on the basis of information provided from the NCBI Entrez Gene 
and Human Protein Reference Database. A: Upregulated proteins in J3T-1 cells. B: Upregulated 
proteins in J3T-2 cells. C: The representative MS/MS spectrum for the peptide sequence matched to 
annexin A2. 
 
Fig.3 Quantitative reverse-transcription PCR (QRT-PCR) validation of candidate proteins shown 
to be differentially expressed in J3T-1 and J3T-2 cells by proteomic analysis. The names of the 
analyzed transcripts are listed along the x-axis and the fold-change increases of each gene in J3T-1 
vs J3T-2 cells (i.e., differences in the relative copy numbers, where 1 represents equal expression 
34 
 
levels in both populations) are listed along the y-axis. Asterisks denote genes that demonstrated 
more than 1.5-fold change in expression levels. 
 
Fig.4 In vivo analysis of the invasive animal model. Macroscopic and microscopic appearance of 
two distinct invasion phenotypes in athymic rats harboring J3T-1 (A) and J3T-2 (B) brain tumors are 
shown. J3T-1 cells form well-demarcated and highly angiogenic tumors. Multiple small satellite 
tumors are also observed at the tumor borders. J3T-2 cells gradually dispersed from the tumor center 
to the surrounding normal brain tissue. All sections are stained with hematoxylin-eosin. Bars 
indicate 300 µm. Immunohistochemical analysis of annexin A2 was performed using rat brain 
samples that harbored green fluorescent protein (GFP)-expressing J3T-1 (C, D, E) and J3T-2 (F, G, 
H) brain tumors. The annexin A2 antibody was visualized using the Cy3-conjugated secondary 
antibody (red). The remarkable staining of annexin A2 in the cytoplasm of J3T-1 tumor cells is 
shown (D, E); J3T-2 tumor cells were hardly stained by the same antibody (G, H). 
 
Fig.5 Results of immunohistochemical analysis of annexin A2 in human glioma samples. 
Representative photomicrographs of paraffin-embedded sections of glioblastomas from patient 2, 
which were immunostained for annexin A2. Cells clustering around the dilated vessels located at the 
border of the tumor are moderately positive for annexin A2 (A). Tumor cells migrating from the 
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tumor center into normal brain parenchyma were mostly negative or very weakly positive for 
annexin A2 (B). Magnification, ×100. Scale bar = 200µm. 
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Table 1 Results of differentially expressed proteins in J3T-1 and J3T-2 cells 
Spot No.† Protein name NCBI-AC‡ MW(Da)/pI AA§(%) MS/MS score Potential biological function 
Up-regulated in J3T-1 
1 Prelamin A/C isoform4 XP_864434 74226/6.57 40 408.01  Structural protein components of the  
           nuclear lamina 
2 Ferritin light chain 2 XP_536874 28397.3/5.39 14 55.69  Storage protein (iron ion transport) 
3 Triosephosphate  NP_001183983 26714.7/6.9 28 82.69  Metabolic enzyme (fatty acid biosynthesis, 
 isomerase         gluconeogenesis, glycolysis) 
4 Annexin A2  NP_001002961 38654.3/6.92 6 26  Calcium-dependent phospholipid-binding
           protein, regulation of cellular growth and in 
           signal transduction pathways 
5 Not identified 
Up-regulated in J3T-2 
6 3-oxoacid CoA transferase 1 XP_536487 64746/7.91 12 103.21  Metabolic enzyme (ketone body catabolism) 
7 Glycine amidinotransferase,  XP_544663 48379.7/8.59 21 119.73  Metabolic enzyme (creatine biosynthesis) 
 mitochondrial 
8 Aminoacyl tRNA  XP_536880 35298.8/7.07 12 37.41  Translation regulatory protein, 
 synthase complex-interacting        protein metabolism 
 multifunctional protein 2-like (AIMP2) 
9 Heterogeneous nuclear  XP_851182 42254.5/9.27 6 29  RNA-binding protein (Regulation of nucleobase, 
 ribonucleoprotein A1 (HNRNPA1)       nucleoside, nucleotide and nucleic acid 
           metabolism) 
10 Sulfotransferase 1C4 XP_531771 35461.8/6.87 10 40.15  Metabolic enzyme (Energy pathway) 
11 Glutathione S-transferase XP_857014 27639.3/6.66 15 35.11  Metabolic enzyme (Energy pathway) 
 theta 1-like isoform4 
12 Elongation factor 2  XP_533949 77884/6.34 5 47.47  Translation regulatory protein, 
           protein metabolism 
13 Septin 11   XP_535616 52111.6/6.24 8 45.17  GTP-binding protein (GTPase activity, 
           cell cycle, vesicle-mediated transport) 
14 Fatty acid synthase  XP_540497 268846.4/5.99 2 87.67  Metabolic enzyme (Energy pathway, 
           catalytic activity) 
15 Dihydropyrimidinase XP_544332 94582/7.08 24 275.93  Metabolic enzyme (Energy pathway, 
 -related protein 3         hydrolase activity) 
16 D-3-phosphoglycerate  XP_849835 56545.8/6.19 17 141.56  Metabolic enzyme (Energy pathway, 
 dehydrogenase-like         catalytic activity) 
17 Aldehyde dehydrogenase, XP_853628 56763.1/6.63 25 176.99  Metabolic enzyme (Energy pathway, 
 mitochondrial isoform 2 (ALDH2)       catalytic activity) 
18 Heterogeneous nuclear  XP_533511 50890.4/5.31 18 116.18  RNA-binding protein 
 ribonucleoprotein K isoform a isoform 1 
 (HNRNPK) 
19 Mitogen-activated   XP_860750 42880.5/6.28 16 88.01  Signal transduction, cell communication
 protein kinase 1         (serine/threonine kinase activity) 
20 Not identified 
21 Not identified 
22 Not identified 
† Protein spot numbers corresponded to the two-dimensional gel electrophoresis image in Fig. 1. 
‡ Accession code in NCBI. 
§ Amino acid coverage (%). 
MW, theoretical molecular weight; Da, Daltons; pI, theoretical isoelectric point.  
Table 2  Details on patients’ age, sex, tumor location, and annexin A2 staining 
Case Age Sex Location  Stainability for annexin A2 
      Perivascular Single invasive 
      tumor cells tumor cells 
1 69 M L. Temporal ++  - 
2 67 M L. Frontal ++  - 
3 76 M L. Frontal +++  + 
4 58 M L. Frontal +  - 
5 75 M L. Temporal +  - 
